FloridaTaper

Category: Iatrogenic Injury

When medical treatment becomes the source of harm, and what to do about it.

  • Fibromyalgia or BIND? A Diagnostic Collision Patients Keep Running Into

    Fibromyalgia or BIND? A Diagnostic Collision Patients Keep Running Into

    You were told fibromyalgia. Could it still be the benzodiazepine?

    It could, and in a patient with your history it often is, at least in part. Fibromyalgia describes widespread pain, exhaustion that sleep does not touch, and a fog that swallows words, and the diagnosis may be accurate as far as it goes. What the chart may not record is a decade on a benzodiazepine, or that the pain arrived during the taper.

    Benzodiazepine-induced neurological dysfunction, or BIND, is the name for the pain, sensory, cognitive, and autonomic symptoms that can follow long-term benzodiazepine use, during a taper and long after it. Put that list beside the fibromyalgia list and the overlap is nearly complete.

    So, which one do you have? For many patients the label depended on which door they walked through, and the rheumatology door had no reason to ask about a sleeping pill. How do you tell the two apart, and why does it matter which name goes first?

    Why do the two pictures look so alike?

    Both fibromyalgia and BIND are understood as a nervous system that has turned up its own volume, so that ordinary signals from muscles and joints are felt as pain. That is as far as the mechanism needs to go. What separates the two is what turned the volume up.

    The Ashton Manual, in Chapter 3, lists pain and stiffness in the limbs, back and neck in its Table 1 of withdrawal symptoms, with fatigue and influenza-like symptoms beside them, which reads like a fibromyalgia note. In BIND, though, the cause has a name and a date on a pharmacy label.

    A homely picture may help, with limits. Two different leaks can leave the same stain on a ceiling, and staring at the stain will not tell you which pipe. While this is not a perfect analogy, since a nervous system can spring two leaks at once, the instruction holds: before anyone treats the stain, ask what changed upstairs, and when.

    The timeline is the first thing that tells them apart.

    Pain and fatigue that began during a taper, or after years of stable dosing once the drug had stopped working, point toward BIND. Pain that predates the first prescription by years points toward fibromyalgia of its own. The question is rarely asked, because the benzodiazepine seldom makes the list of suspects. It is usually filed under treatments.

    A common pattern is a woman in her fifties who took a benzodiazepine for sleep for fifteen years, was taken off it over a few weeks, and six months later carries a fibromyalgia diagnosis and a prescription for pregabalin. The taper is nowhere in the rheumatology note. Nobody lied, and nobody connected the dates.

    Raising the history yourself can feel like confessing to something. Physical dependence is not addiction. It is the nervous system’s adaptation to a medication taken as prescribed, and what follows a dose reduction is that adaptation unwinding, with no verdict on your character attached.

    The autonomic and sensory picture is the second.

    BIND tends to bring a louder autonomic picture: temperature swings, a pounding heart on standing, blood pressure that lurches, sweating with no exertion, and gut symptoms that track dose changes. Fibromyalgia can include some of this, but it is seldom the loudest part.

    Sensory hypersensitivity is the other tell. The Ashton Manual calls a heightened sensitivity to hearing, sight, touch, taste and smell a characteristic feature of withdrawal, with clocks unbearably loud and ordinary light dazzling. Patients with BIND also describe new reactions to medications and foods they once tolerated, which is far less usual in a fibromyalgia history.

    The same collision has sent patients with BIND through a multiple sclerosis workup and into allergy testing. Each time a real symptom pointed at the wrong diagnosis.

    Windows and waves are the third.

    Fibromyalgia fluctuates, but its swings do not usually follow a calendar you can read. BIND does. The Ashton Manual describes symptoms that wax and wane from day to day and week to week, with windows of normality, hours or days of feeling positively well, appearing after some weeks. Patients call the bad stretches waves.

    The difference is time-locking. Waves in BIND tend to follow a dose reduction by a few days, or a new medication, an infection, or a hard week, and the window afterward is often unmistakable. So, keep a calendar with the reductions on one side and the worst days on the other, and see whether they keep landing in the week or two after each cut.

    Can you have both?

    Yes, and many patients do. Fibromyalgia that predates the benzodiazepine by years is real, and a taper can make it far worse for a time, since one sensitized nervous system is being pushed from two directions. The honest chart entry is then fibromyalgia with a BIND contribution, or, often, BIND that happens to meet fibromyalgia criteria.

    Dr. Leeds’ view is that the earlier label need not be erased. Both can stand, each explaining part of the picture, and while the taper is under way or recently finished, the BIND piece leads.

    The standard fibromyalgia drugs each carry a second taper inside them.

    The medicines most often prescribed for fibromyalgia are duloxetine and milnacipran, which are serotonin and norepinephrine reuptake inhibitors, or SNRIs, the gabapentinoids pregabalin and gabapentin, and amitriptyline, a tricyclic antidepressant. Whether one helps you is between you and your doctor. What is not in question is that each brings its own dependence or discontinuation problem into a nervous system that already has one.

    Gabapentin and pregabalin produce physical dependence of their own, with a withdrawal syndrome that looks, in many respects, like the one you are already in. Taken alongside a benzodiazepine they also add to its sedation and can slow breathing, so every prescriber on your list needs to know about the benzodiazepine.

    The SNRIs are a different class, but their discontinuation symptoms are real and can be slow to taper, which is why the Maudsley Deprescribing Guidelines give antidepressants and gabapentinoids their own sections beside the ones for benzodiazepines. Amitriptyline has a discontinuation syndrome of its own, and at the low doses used for pain it is often as much a tolerance problem as a taper problem, since its anticholinergic effects land hard on a nervous system already reacting to everything.

    So, the price of short-term relief is often a second taper later, and for a patient still on the benzodiazepine, one more drug in the deprescribing plan. That is not a rule against them, and some patients, with their doctor, decide that relief now is worth it, so long as the price is written down before the first dose rather than discovered after the last.

    What about exercise and therapy?

    Graded exercise, where the amount goes up on a schedule regardless of how you feel, is standard fibromyalgia advice. Patients with BIND often describe a crash a day or two after exertion, and a schedule that ignores the crash produces more of them. The Ashton Manual recommends regular moderate exercise during withdrawal, and moderate is the word to hold onto.

    Pacing means doing what today allows, stopping before the crash, and adding a little as the windows lengthen. It is slower than a graded program, and it is the approach that tends to hold up in BIND, because it is the one patients keep up.

    Cognitive behavioral therapy, or CBT, can help when it is offered as tools for living with a neurological syndrome, and lands as one more dismissal when it is offered as treatment for a psychological condition. Most patients with BIND have collected several already.

    Sometimes the pain is neither, and it needs to be checked.

    Both labels come after other things have been looked at. Widespread pain with a fever, unexplained weight loss, night sweats, hot or swollen joints, a new rash, weakness or numbness on one side, or pain with no relationship to your dose changes should be examined rather than filed under either name.

    Chest pain, a seizure, a sudden loss of vision or hearing, or thoughts of harming yourself are reasons for emergency care that day, and in the United States a call or text to 988 reaches the Suicide and Crisis Lifeline. A taper never makes any of those safe to wait on.

    Neither does it make stopping safe. The 2020 United States Food and Drug Administration (FDA) benzodiazepine label update warns that abrupt discontinuation or rapid dose reduction can bring on acute withdrawal reactions, including seizures, and describes a protracted withdrawal syndrome lasting weeks to more than a year. If the pain is the taper, the answer is a slower taper, decided with your doctor, never a faster one.

    The diagnosis is worth revisiting over time.

    Fortunately, BIND has a direction. The Ashton Manual says a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time, and BIND-dominant pictures tend to keep improving for months, sometimes years, after the taper is complete. No one can give you the date, and an honest doctor will say so.

    That direction is also a diagnostic test. Whatever pain and fatigue remain after the BIND curve has run its course are better evidence for fibromyalgia of its own, and can be treated as such once the nervous system is better able to tolerate treatment.

    So, treat the line on your chart as a working hypothesis rather than a verdict. Bring the calendar and the dates, and ask your doctor which name should lead for now. As the waves thin out, the two of you can look again, and the answer may be smaller than it is today.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • When a Neurologist Orders an MS Workup for a Patient With BIND: What the Differential Should Include

    When a Neurologist Orders an MS Workup for a Patient With BIND: What the Differential Should Include

    A patient with paresthesias, tremor, fatigue, cognitive dysfunction, and sensory disturbances arriving at a neurology clinic will often leave with an order for a multiple sclerosis (MS) workup. The reasoning is straightforward: the symptom list triggers the MS differential, and a prudent neurologist wants to exclude a treatable and progressive neurological disease before settling on less specific explanations. For patients with benzodiazepine-induced neurological dysfunction (BIND), this is usually the right clinical instinct to follow, since MS can occur in patients who happen to have a benzodiazepine history, and its exclusion is genuinely useful. What often goes wrong is what happens after the MS workup returns negative, and what the rest of the differential should have included alongside MS from the beginning.

    Why the MS Differential Gets Triggered

    Several features of BIND present as neurological symptoms that a neurologist examining the patient for the first time could reasonably read as MS.

    Paresthesias and dysesthesias are the most common trigger. Tingling, numbness, burning sensations, and altered tactile perception can appear in various distributions. MS classically produces patchy, asymmetric sensory changes corresponding to demyelinating lesions, while BIND produces more diffuse, bilateral sensory symptoms, but the distinction is not always clean at presentation. Both conditions also produce substantial fatigue that is out of proportion to activity.

    Cognitive dysfunction overlaps as well. MS can produce slowed processing speed, attention difficulties, and executive dysfunction, and BIND produces similar cognitive features, so a neurologist evaluating the cognitive complaint alone may consider MS reasonably. Visual symptoms overlap too. Blurred vision, floaters, and altered visual perception occur in both. Optic neuritis is a defining MS event; BIND does not produce optic neuritis but can produce visual symptoms that prompt an evaluation for it.

    Tremor is common in BIND and can also appear in MS. Ataxia and coordination difficulties are less common in BIND than in MS but can occur, and both conditions can affect balance and gait. Autonomic features overlap as well: MS can involve urinary urgency, bowel changes, and sexual dysfunction, while BIND frequently involves broader autonomic dysfunction.

    One caution belongs here, because overlap is not sameness. Sudden loss of vision in one eye, new weakness or numbness confined to one side of the body, trouble speaking, or a first seizure are not symptoms to wait out as withdrawal; they need emergency care the same day, so call emergency services if they appear.

    What the MS Workup Typically Shows

    The standard MS workup includes magnetic resonance imaging (MRI) of the brain and cervical spine with and without contrast, evaluation of cerebrospinal fluid (CSF) for oligoclonal bands and the immunoglobulin G (IgG) index, and often evoked potentials. Supportive laboratory evaluation typically includes vitamin B12, thyroid function, and other mimics.

    There is no BIND-specific imaging or spinal fluid literature to point to, so what follows is clinical experience rather than a published series. In Dr. Leeds’ experience, and in what patients in the BIND community consistently report, the structural workup comes back normal.

    MRI is usually unremarkable. There are no demyelinating lesions in the periventricular, juxtacortical, infratentorial, or spinal cord distributions that MS diagnostic criteria require, and brain parenchyma appears normal or shows age-appropriate changes.

    CSF is usually negative for oligoclonal bands not present in serum, the IgG index is not elevated, and CSF cell counts and protein are unremarkable. Evoked potentials, when performed, tend to be normal or non-specific.

    The workup essentially excludes MS.

    What Should Be Part of the Differential Alongside MS

    A neurologist evaluating the same symptom picture should ideally consider several additional diagnoses from the start, not only after MS has been excluded.

    BIND itself belongs on the list. In a patient with long-term benzodiazepine exposure and a recent taper or discontinuation, BIND is a specific diagnostic candidate supported by an established clinical framework. The clinical features, which are time-locked to benzodiazepine changes, accompanied by autonomic and sensory hypersensitivity, and fluctuating in the waves-and-windows pattern, are recognizable.

    Vitamin B12 deficiency produces peripheral neuropathy, paresthesias, ataxia, and cognitive symptoms. Serum B12 with methylmalonic acid and homocysteine for borderline values is appropriate. Severely low vitamin D has been associated with neurologic symptoms and is cheap to exclude. Both hyperthyroidism and hypothyroidism can produce cognitive, autonomic, and motor symptoms, and thyroid-stimulating hormone (TSH) is the standard screen.

    In regions where Lyme disease is common, or with a compatible exposure history, Lyme serology is worth including, with the understanding that the tests have limits and a result needs interpretation rather than a glance. Celiac disease can produce peripheral neuropathy, ataxia, and cognitive symptoms, sometimes as the presenting features. Tissue transglutaminase immunoglobulin A (IgA) with total IgA is the screening combination.

    Other demyelinating conditions, including neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG) antibody disease, have their own antibody tests, as does autoimmune autonomic neuropathy, and a neurologist will know when the picture calls for them.

    Medication effects deserve a full review. Not only benzodiazepines but also fluoroquinolones, metronidazole, chemotherapy agents, statins in some patients, and other medications can produce neurological symptom pictures. The full medication list belongs in every workup of this kind.

    Functional neurological disorder (FND) has specific rule-in criteria and should not be a diagnosis of exclusion after a normal workup. The clinician should test for FND signs specifically (Hoover’s sign, tremor entrainment, tubular visual fields) and apply the label only when they are present, not when everything else is negative.

    Where the Diagnostic Error Usually Happens

    The typical failure mode in this clinical scenario is a neurologist who completes an MS workup, finds it negative, and concludes “no neurological disease.” The symptoms are then attributed to anxiety, functional etiology, or somatization, and the patient is referred back to psychiatry or discharged from neurology follow-up.

    This is an error for several reasons.

    MS-negative does not mean neurological-disease-negative. The MS differential is narrow; many non-MS neurological conditions produce similar symptom pictures and require different tests to identify.

    BIND is a neurological condition, not a psychiatric one, even though it lacks the structural imaging findings of classical neurology. It is also a condition of physical dependence, which is not addiction: the nervous system adapted to a prescribed medication and is now destabilized by its reduction or absence, and nothing about that requires a psychiatric or addiction explanation. A neurologist who does not consider pharmacologically-driven neurological dysfunction as part of the differential is working with an incomplete framework.

    Defaulting to FND without rule-in criteria produces the same misdiagnosis pattern seen elsewhere on this site, where BIND is relabeled as an unrelated condition, and the same collision plays out when BIND is mistaken for fibromyalgia. FND exists as a positive diagnosis; it is not “everything else has been ruled out.”

    What the Patient Can Ask For

    For a patient headed into an MS workup in the context of a benzodiazepine history, several requests shift the evaluation toward a more useful outcome.

    Ask that the benzodiazepine history and taper timeline be explicitly documented in the neurology note. A workup pursued in the context of acknowledged benzodiazepine exposure produces more useful subsequent discussion than a workup that implicitly treats the patient as free of relevant medication history.

    Request that BIND be considered as one possibility alongside MS. Providing background on the BIND framework in advance can orient a neurologist unfamiliar with it.

    Ask that the workup include B12, methylmalonic acid, homocysteine, vitamin D, TSH, celiac serology, and Lyme serology (where exposure is plausible) alongside the MRI and CSF. These are low-cost additions that broaden the differential meaningfully.

    If the MS workup is negative, request that the neurologist document specifically which diagnoses are being considered next rather than defaulting to “non-neurological” or “functional.” A differential explicitly including BIND, mimic conditions, and specific alternative neurological diagnoses is more useful for future clinical care than a negative conclusion.

    Ask for follow-up rather than discharge if BIND is being considered. BIND patients benefit from neurology follow-up even when the structural workup is negative; autonomic and sensory symptoms may require specific management, and the label of a recognized syndrome in the chart aids subsequent care.

    What a Good Neurology Note Looks Like

    For a BIND patient whose MS workup returned negative, a well-constructed neurology note reads something like this: structural MS workup is negative; the clinical picture is compatible with benzodiazepine-induced neurological dysfunction; alternative mimics (B12 deficiency, thyroid dysfunction, Lyme disease, celiac disease) have been evaluated and are not contributory; ongoing management will focus on the benzodiazepine taper and recovery with follow-up at regular intervals.

    Compared to a note that says “no evidence of neurological disease; recommend psychiatric follow-up,” the useful version accomplishes several things: it acknowledges the syndrome by name, documents the negative workup in context, aligns future clinicians with the relevant framework, and preserves the clinical relationship for ongoing care.

    The point of an MS workup in a BIND patient is to exclude MS. The workup accomplishes that efficiently when pursued appropriately. What matters equally is that the broader differential is considered from the start, so that a negative MS workup narrows the question rather than ending it.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • When Benzodiazepine-Induced Neurological Dysfunction (BIND) Is Misdiagnosed as Functional Neurological Disorder, How Do You Get the Chart Corrected?

    When Benzodiazepine-Induced Neurological Dysfunction (BIND) Is Misdiagnosed as Functional Neurological Disorder, How Do You Get the Chart Corrected?

    Why does a functional label follow you from one doctor to the next?

    Because a chart never forgets and rarely reconsiders. When benzodiazepine-induced neurological dysfunction, or BIND, is written up as functional neurological disorder, or FND, the label does not stay in one neurologist’s note. It travels, and every clinician who opens the record afterward reads it before they read you.

    It shapes how a new tremor gets interpreted, which specialists will accept a referral, and whether an insurer will pay. Yet, the label was usually applied in good faith, by a doctor working inside a framework that has no line for BIND.

    So, why does the mix-up happen, and what changes the record once it has? The second answer is paper.

    What is BIND, and why does it look like nothing on a scan?

    BIND is the name for the neurological, cognitive, and autonomic symptoms that can persist after long-term benzodiazepine use, including in people who tapered slowly and did everything right. The symptoms begin during use, during dose reductions, or after the last dose, and that timing is the heart of the diagnosis.

    Professor C. Heather Ashton described the picture years ago without the acronym. Chapter III of the Ashton Manual, in its Table 3 of protracted withdrawal symptoms, lists tinnitus, tingling, numbness, burning limb pain, muscle pain, cramps, tremor, jerks, and shaking attacks, and says they gradually recede but may last at least a year and occasionally several. The 2020 United States Food and Drug Administration (FDA) label update says as much: physical dependence can occur when a benzodiazepine is taken steadily for several days to weeks, even as prescribed, and a protracted withdrawal syndrome can last from weeks to as long as twelve months.

    Why is the scan normal? The first chapter of the Ashton Manual describes the receptors benzodiazepines act on becoming less responsive during long use. One theory is that they recover slowly afterward, a change in how the nervous system is tuned rather than in its structure, and no routine test measures tuning.

    Functional neurological disorder is supposed to be a rule-in diagnosis.

    FND is a real diagnosis, and a neurologist is supposed to make it on positive findings rather than on the absence of them. The rule-in signs are specific: Hoover’s sign for functional weakness, tremor that falls into step with a rhythm the examiner sets, and movements that stop when your attention is pulled elsewhere.

    In practice it is not always arrived at that carefully. A normal magnetic resonance imaging (MRI) scan, a normal electroencephalogram (EEG), and no fit to a standard syndrome, and the note says functional because nothing else was on the menu. That default is where the BIND patient gets caught, and the Maudsley Deprescribing Guidelines make the point that withdrawal effects are often mistaken for a return of the original condition or for a new physical or mental health condition.

    Three things about BIND make the mix-up easy.

    First, the tests are normal. There is no MRI finding for BIND and the EEG shows no seizure activity. Professor Ashton recorded three patients whose numbness, spasms, and double vision were diagnosed as multiple sclerosis, a label that disappeared with the symptoms once they were off the drug. The same pattern appears in other specialties when jaw tension and neck dystonia in withdrawal are read as temporomandibular disorder.

    Second, some BIND signs look functional on the surface. Tremor that waxes and wanes, symptoms that shift with attention, and bad days followed by ordinary ones are all real in BIND, and all sit on the list neurologists are taught to read as functional.

    Third, the medication history is thin in the chart. If your years on a benzodiazepine and the taper that followed are not at the top of the history, the neurologist may never connect the picture to the drug. And, when the taper is recorded, it usually reads “completed uneventfully six months ago,” which few neurologists are trained to weigh as a live variable.

    Start with a written medication timeline.

    The most useful document you can bring is one page. It lists the benzodiazepine by name, the dose, how long you took it, how the taper went and when it ended, and beside that, when each symptom began and how it has behaved since. Ask that the page be scanned into the chart as a document, not summarized by whoever is typing.

    Write it in the vocabulary of prescribed dependence. If the chart files your Klonopin (clonazepam) under past habits rather than under prescribed medications, every later reader starts from the wrong premise. Physical dependence is not addiction. A person who took a medication as prescribed and now has symptoms after stopping it has a medical condition caused by the medication, and a timeline that says so plainly does more work than any argument in a visit.

    While you are writing it, resist any urge to prove a point by changing your taper. The 2020 label update is explicit that stopping a benzodiazepine abruptly, or reducing it too quickly, can bring on withdrawal reactions, including seizures, that can be life-threatening.

    Ask that BIND be named, with its expansion.

    Clinicians write what they are given. A short line you hand over, “presentation consistent with benzodiazepine-induced neurological dysfunction (BIND) following prescribed use and a completed taper,” gives the record a searchable term the next clinician can act on, and preserves the fact that the injury was iatrogenic, meaning caused by treatment.

    Bring supporting material, kept short. The 2020 FDA label update is the strongest single page, because its boxed warning, which your neurologist can look up, says continued use can lead to clinically significant physical dependence. The Maudsley Deprescribing Guidelines are a reference text neurologists recognize, and the Benzodiazepine Information Coalition, or BIC, on whose medical advisory board Dr. Leeds serves, publishes clinical resources written for this conversation.

    If FND is already in the chart, ask for a written amendment.

    The Health Insurance Portability and Accountability Act, or HIPAA, gives you the right to ask that a record you believe is inaccurate be amended. The request goes in writing to the practice or hospital that created the note, and a refusal must come back to you in writing, ordinarily within sixty days. Keep it factual: the diagnosis does not reflect the medication history and the symptom chronology, and you are asking that BIND be added, alongside FND or as a correction.

    They may say no. Unfortunately, a denial by itself does not make your request travel with the record. What does is a statement of disagreement, a short written note you file after the denial. Once it is on file, the provider must include your request, the denial, and your statement whenever that part of the record is disclosed, and without it they are included only if you ask for that separately.

    So, if the answer is no, file the statement. It is the step most patients skip, and the one that does the work. If the answer is yes, ask which records were amended and whether the correction reached the other clinicians who received the original.

    Ask that the negative findings be written down.

    There is a difference between a note that says “functional etiology suspected” and one that says “Hoover’s sign negative, tremor did not entrain, FND rule-in signs tested and not present.” The first is an impression. The second is a set of findings, and findings are what the next neurologist reads.

    So, when an examiner tests for those signs and does not find them, ask that the absence be recorded affirmatively, and ask in the room. That small request quietly removes the floor from under a functional label.

    The record is changed with paper, not with persuasion.

    Do not argue the diagnosis in the visit. The mechanism that produced it is institutional, fifteen-minute appointments and diagnostic defaults, and none of that is reversed by one patient disagreeing well.

    Do not avoid mental health care out of fear that it confirms the functional label. BIND regularly brings anxiety, low mood, and trauma responses that deserve care in their own right, and treating them does not retroactively validate an FND diagnosis. Choose it with open eyes, since standard psychiatric treatment can make BIND worse, and if thoughts of harming yourself appear, call or text 988 or go to the nearest emergency department.

    And do not let “it is probably BIND” become a label of its own. New weakness or numbness on one side of the body, a first seizure, a sudden loss of vision or hearing, a severe sudden headache, chest pain, or trouble speaking need emergency care the same day, whatever the chart says. BIND explains a great deal, and it does not explain everything.

    The clinicians who wrote the label are usually not the problem.

    Most neurologists who apply an FND label do it in good faith, within a diagnostic framework that has not yet made room for BIND, and the path forward is clinician education more than confrontation. Over time the label often softens and drops out of later notes as the paper keeps arriving.

    Fortunately, this is a syndrome with a direction. The Ashton Manual says that a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time, and a record corrected one page at a time tends to lag behind the nervous system it describes. You will probably be better before the chart catches up, and the pages you filed will still be there for whoever reads it next.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Does Long-Term Clorazepate Use Set Off a Prescribing Cascade of New Diagnoses and New Drugs?

    Does Long-Term Clorazepate Use Set Off a Prescribing Cascade of New Diagnoses and New Drugs?

    What is a prescribing cascade?

    A prescribing cascade is what happens when a side effect of one medication is mistaken for a new illness and treated with a second medication, whose side effects are mistaken for a third illness and treated again. Nobody plans one, and each step looks reasonable at the time.

    Long-term benzodiazepine use is a reliable place for a cascade to begin, because the drug’s later effects look so much like other diseases. Clorazepate, sold as Tranxene, produces a slow and quiet version of the pattern. So, how does one prescription turn into four, and how do you get the chain to stop?

    Why is clorazepate so hard to see through?

    Clorazepate is a prodrug: the tablet you swallow is not the active drug. Once swallowed, it is quickly converted, by a reaction the label calls decarboxylation, into nordiazepam, also known as desmethyldiazepam.

    The Ashton Manual, in Chapter I, Table 1, lists the half-life of clorazepate’s active metabolite at 36 to 200 hours, and the drug’s own label gives nordiazepam an apparent half-life of about 40 to 50 hours and says it shows moderate accumulation with repeated dosing. As a result, levels build for weeks after daily dosing starts and fall just as slowly when a dose is lowered.

    An analogy that might help is a bathtub with a partly open drain. Open the tap a little and the water rises for a long time before it settles, and close it a little and it drops just as slowly. While this is not a perfect analogy, it explains why you can feel worse three weeks after a change you have already stopped thinking about, and why a reduction should be judged weeks later, not the next morning.

    Your anxiety got worse on a steady dose. Is that the drug?

    Many people on a long-term benzodiazepine find that anxiety creeps back after years on the same dose, sometimes with tremor, tingling, a pounding heart, or panic that never happened before. The Ashton Manual’s Chapter I section on tolerance describes exactly this: as the brain adapts, withdrawal symptoms can emerge even while the drug is still being taken.

    Physical dependence is not addiction. A person who took clorazepate as prescribed for ten years has a body that adapted to it, a medical condition caused by the prescription, and that adaptation produces these symptoms.

    Unfortunately, the usual response is more treatment: a higher benzodiazepine dose, a selective serotonin reuptake inhibitor (SSRI), or an antipsychotic. While any of these may bring a few weeks of relief, the tolerance pattern tends to return at the new level, and nobody asked whether the anxiety was the drug’s own effect.

    You are tired and flat, and someone called it depression.

    Long-acting benzodiazepine metabolites cause daytime drowsiness and slowed thinking, and on clorazepate that sedation is steady rather than in waves. Too often, it gets relabeled as fatigue or depression and treated with an antidepressant, occasionally a stimulant, while the benzodiazepine’s share goes unexamined.

    People who have taken a benzodiazepine for years also describe a narrowed emotional range, which Professor C. Heather Ashton called “emotional anaesthesia” in Chapter I of the Ashton Manual, and a doctor can read that flatness as anxiety under control. Emotional blunting on Klonopin follows the same shape, and the same misreading.

    Low mood still deserves to be taken seriously. If you are having thoughts of harming yourself, call or text 988, the Suicide and Crisis Lifeline, or go to an emergency department, and let the drug question wait.

    Your memory is slipping, and the word dementia came up.

    The Ashton Manual notes that complete tolerance to the effects on memory and cognition does not seem to occur, and that in older people benzodiazepines can produce confusion, unsteadiness, and what Chapter I calls “pseudodementia.” In a younger person the same fog gets worked up as attention deficit hyperactivity disorder (ADHD), with a stimulant to follow, and in an older person as early dementia.

    Fortunately, this impairment is often at least partly reversible once the drug is slowly reduced, which makes either label costly. A workup that never asks what you have been taking for a decade can miss the one reversible cause on the list.

    You cannot sleep, so a second sedative was added.

    Benzodiazepines taken during the day can disturb sleep at night, especially once tolerance to the sedative effect has set in, and the complaint that follows is insomnia. The common answer is a second sedating drug on top of the first, whether quetiapine, trazodone, or zolpidem, and now you take two sedatives with overlapping risks.

    If the sleeping pill helps for a while and then stops, that is the same tolerance pattern arriving on the second drug. Before a third is added, the older prescription is the one to ask about.

    Falls, an irritable streak, and a racing heart each got their own workup.

    Oversedation is more marked in older people and, as the Ashton Manual puts it, may contribute to falls and fractures. When a fall is treated as a bone problem and nobody reviews the medication list, the drug that caused the fall stays on the list.

    Rarely, a patient becomes irritable, impulsive, or agitated on a benzodiazepine, which the clorazepate label calls a paradoxical or disinhibitory reaction and which the Ashton Manual says is most frequent in older people and children. Read as new bipolar disorder or a personality problem, the change earns a mood stabilizer or an antipsychotic, and the cause is never named.

    Gut and autonomic symptoms do the same. Constipation, reflux, palpitations, temperature swings, and dizziness on standing can appear during long-term use, and each can generate its own specialist, testing, and drug. Dysautonomia after long-term benzodiazepine use deserves the drug question before the testing begins.

    None of this means every new symptom is the benzodiazepine. Chest pain, a seizure, fainting, sudden loss of vision or hearing, new weakness on one side, or a fall with a blow to the head are emergencies that need 911 or an emergency department, whatever list you are on.

    Why does this keep happening to careful doctors?

    Of course, prescribing cascades come from how medical care is arranged, far more than from careless doctors. Visits are short, specialists work in silos, and the fastest path out of a short visit is a new prescription.

    Electronic records list recent additions at the top and old renewals at the bottom, and a prescription refilled every ninety days for ten years stops looking like a decision and starts looking like furniture. And, when a patient suggests the old prescription as the cause, the reply is often reassurance rather than a review. Yet, this is not a plea against doctors, most of whom were never taught about tolerance and work in a system that pays for additions, not subtractions.

    How do you interrupt a cascade?

    The first move is a question, asked before any new prescription: could this be the drug? For any new symptom on a long-term benzodiazepine, the medication list, with start dates and past dose changes, is the first thing to check.

    The second move is to consider a reduction before an addition. If the new symptom might be tolerance, sedation, or disinhibition, a slow, small dose reduction made with your prescriber tells you more than a new drug would, because the symptom either eases or does not. Both the Ashton Manual and the Maudsley Deprescribing Guidelines describe such symptoms being mistaken for the original condition or a new illness, and this step follows from that, though neither states it as a rule.

    A reduction is never the same as stopping. Since the 2020 United States Food and Drug Administration (FDA) label update, clorazepate carries a boxed warning that abrupt discontinuation or rapid dosage reduction can precipitate acute withdrawal reactions that can be life-threatening, and the label names seizures among them and calls for a gradual taper. The pace is between you and your doctor, with you directing the speed as tolerated.

    The third move is a standing review of every chronic medication at a visit set aside for it. How often that would catch a cascade is not a number this article can give you, only a pattern that doctors who taper these drugs see often, and experience varies.

    What is different when the drug is clorazepate?

    Clorazepate’s wrinkle is that nordiazepam builds and clears so slowly that its sedation and fog develop over weeks and outlast any single dose, which makes them hard to connect to the tablet. The effect of lowering it may not be fully visible for two to three weeks, so reductions are usually made less often than with a short-acting benzodiazepine, and each is judged with patience.

    Dr. Leeds’ view, shared by the sources this site cites, is that the reduction is small, slow, and patient directed. On clorazepate that patience matters twice over, because the drug’s own timetable is slow.

    A composite pattern: a patient in their sixties on clorazepate for years is seen for tiredness and started on an antidepressant, then for poor sleep and given a sleeping pill, then for confusion and sent for a memory workup. Nobody on that chain had a reason to pull the first prescription forward. The patient’s own question, at the fourth visit, finally did.

    What happens when you ask the question yourself?

    You are allowed to ask whether an old prescription could be causing a new symptom, and to ask again if the first answer is reassurance. Bring the whole list, with dates, and ask your doctor to look at it with you before the next addition.

    Still, time is on your side once the drug question is in play. Sedation, fog, and flatness from a long-acting benzodiazepine tend to lift as the level comes down over the weeks the drug takes to leave, and whatever remains is a shorter, more honest list to bring back to your doctor.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Seroquel for Sleep: When an Antipsychotic Becomes the Problem

    Seroquel for Sleep: When an Antipsychotic Becomes the Problem

    Why would a doctor give you an antipsychotic to help you sleep?

    Seroquel, or quetiapine, is an antipsychotic. Its label from the United States Food and Drug Administration (FDA) lists schizophrenia and bipolar disorder, and the extended-release label adds a role as an add-on to an antidepressant in major depression. Insomnia appears nowhere on either list.

    Yet, if you are partway through a benzodiazepine taper and sleeping badly, someone has probably already offered you a small bedtime dose as something mild for sleep. At low doses quetiapine mostly blocks the histamine H1 receptor, the same receptor that older allergy pills block, and blocking histamine makes people drowsy.

    It is also not a controlled substance, and the Ashton Manual, in Chapter II, warns against z-drugs for withdrawal insomnia because they act like benzodiazepines. So, the patient who would have declined an antipsychotic accepts a sleep aid, and nobody at the visit uses the first word. What does it cost to borrow sleep from one?

    What does a small dose of quetiapine do to the rest of you?

    More than the phrase “something mild” suggests. The label warns that quetiapine can raise blood sugar, disturb blood lipids, and add weight, and it advises checking all three during treatment, which often does not happen when the drug was prescribed only for sleep.

    The label also warns that quetiapine can drop your blood pressure when you stand, with dizziness and in some people fainting, which for a person who gets up at night is a fall waiting to happen. And, it carries an anticholinergic load, bringing dry mouth, trouble emptying the bladder, and constipation severe enough that the label warns of bowel obstruction.

    Akathisia, an inner restlessness that makes it hard to sit still, can appear even at sleep doses in clinical experience, and it is regularly mistaken for worsening anxiety, which prompts a higher dose that makes it worse.

    Quetiapine also lengthens the QT interval, a measure on an electrocardiogram of how long the heart takes to recharge between beats. So, the label says to avoid combining it with other drugs that do the same, including certain heart-rhythm drugs and some antibiotics.

    Some of these are not withdrawal and should not be waited out. A pounding or irregular heartbeat, a high fever with stiff muscles, severe belly pain with vomiting, or extreme thirst and urination each need a doctor promptly.

    Fainting, chest pain, a seizure, or thoughts of harming yourself are emergencies, so call 911 or go to the emergency department. Call or text 988 if the thoughts are of self-harm, a risk the label carries as a boxed warning for young people treated for depression.

    Can you become dependent on a sleep dose of quetiapine?

    Yes. The label says that acute withdrawal symptoms, insomnia, nausea, and vomiting among them, have been described after abrupt cessation of antipsychotics including Seroquel, and its longer list adds headache, diarrhea, dizziness, and irritability. Its instruction is four words long: gradual withdrawal is advised.

    Professor Ashton wrote in Chapter III of the Ashton Manual that withdrawal reactions are a normal response to stopping many long-used drugs, antipsychotics among them. Nobody uses the vocabulary of misuse for a sleep pill, yet the same people may quietly decide that you must need it.

    Physical dependence is not addiction. Your body adjusted to a drug that arrived every night for months, and it objects when the drug is gone, a medical condition caused by the prescription and nothing more.

    How long does it last? While the label says the symptoms usually resolve within about a week, that figure comes from short trials at treatment doses, and none of the sources this site cites can say whether some people have a longer course. In clinical experience it varies.

    Why is the rebound insomnia not your old insomnia coming back?

    Because the timing and the shape give it away. Insomnia heads the label’s list of discontinuation effects, and patients who stop quetiapine suddenly often describe several nights of almost no sleep, vivid dreams when sleep finally comes, and a wired, agitated feeling by day. The original complaint was rarely that dramatic.

    One likely explanation is that histamine was held down every night, the brain compensated, and when the drug leaves, the histamine system overshoots for a while, though that is a mechanism nobody has measured well. The Ashton Manual describes a similar overshoot of dreaming sleep after benzodiazepine withdrawal in the Chapter III section on insomnia, nightmares, and sleep disturbance. Two rebounds at once is a bad night.

    The reflexive conclusion is that the medication is needed after all, and the tablets go back in the drawer by the bed. In Dr. Leeds’ view that conclusion is usually wrong, because rebound is withdrawal, and a drug restarted every time the rebound appears never gets tapered at all.

    How does one taper turn into two?

    Dr. Leeds sees the pattern often enough to describe it as one story: a patient months into a careful taper mentions poor sleep, a small bedtime dose of quetiapine is added, and the sleep improves for a few weeks. A year later the patient is off the benzodiazepine and asking how to stop the sleep pill, a second withdrawal created by the management of the first.

    While this is not a perfect analogy, adding quetiapine to cover taper insomnia is a bit like taking out a second loan to make the payments on the first. The payments stop hurting for a while. Yet, you now owe two lenders, and the second one collects on its own schedule, with terms you were never shown.

    So, ask to see the repayment terms before you sign, which in plain language means the exit plan. Unfortunately, the second loan is rarely explained as a loan.

    Insomnia during a benzodiazepine taper is common enough to have its own article on this site. A side effect of one drug is a reason to reopen the conversation about that drug and its pace, not a reason to add a second drug on top of it.

    Professor Ashton said as much in the Chapter III section on extra medication: sedating relatives of the major tranquilizers, sometimes prescribed during withdrawal, can cause movement disorders and are no substitute for a benzodiazepine.

    The benzodiazepine comes off first, and the two never move together.

    That is Dr. Leeds’ view, and the reasoning is simple: two withdrawals at once multiply the sleepless nights and make it impossible to tell which drug is causing what.

    Finish the benzodiazepine taper, give the nervous system months to settle, and then take up the quetiapine with the prescriber. Neither drug ever comes off abruptly, whatever order you and your doctor settle on.

    There is no one-size-fits-all order. While a person who took the antipsychotic for years before the benzodiazepine has a different history to weigh with their doctor, the rule that survives every history is that the two do not move together, even when that means carrying a drug you never wanted for another year.

    How slowly should quetiapine come down?

    Slowly, in steps that shrink as the dose falls. The Maudsley Deprescribing Guidelines set out the principle behind that shape, called hyperbolic tapering: a drug’s effect on its receptors does not fall in a straight line with the dose, so the reductions near the end need to be the smallest.

    The Maudsley volume in print covers antidepressants, benzodiazepines, gabapentinoids, and z-drugs, and a companion volume on antipsychotics has been announced but has not arrived, so for now there is no Maudsley quetiapine schedule to quote, whatever a forum post claims. That leaves the label’s “gradual withdrawal is advised” and clinical experience, which varies, and neither belongs on a website as a milligram schedule.

    The smallest tablet on the label is 25 mg, so near the end tablets get split, a compounded liquid is one option for the last stretch, and how far down to go is a matter for you and your prescriber, not a search engine.

    When a reduction brings a rebound flare, holding at the current dose until the nights settle keeps the ground you gained. And, sleep work in parallel gives the brain something to lean on other than a receptor.

    Cognitive behavioral therapy for insomnia (CBT-I) is one route, and the Ashton Manual’s plain measures for withdrawal insomnia, no caffeine or alcohol near bedtime and exercise by day, are another. Some patients find one enough and some use both.

    What should you ask before the first tablet?

    Fortunately, the questions are simple, asking them is not an act of defiance, and they are the ones you would put to any lender before signing.

    Why this drug for sleep, when its own label never mentions insomnia? What is the plan for coming off of it, and when will that plan be revisited? What will be checked along the way? What are the alternatives, including a slower benzodiazepine taper and no additional medication at all?

    You are allowed to decline, and to change your mind later without losing your doctor’s goodwill. Informed consent means the risks come first, the exit plan is part of the first conversation, and the decision remains yours as the months go by.

    A person who takes quetiapine with open eyes and a written exit plan is in a different position from one who was handed it as something mild. If you are already in the second position, there is no cause for alarm, only a plan to write down at your next visit.

    The drug then comes off the same way it should have gone on, slowly and on purpose, with your doctor as a partner. Nobody described that part at the first visit, which is one more reason to put it on the agenda for the next one.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Gabapentin Dependence: The Overlooked Deprescribing Challenge

    Gabapentin Dependence: The Overlooked Deprescribing Challenge

    Can you become dependent on gabapentin at the dose your doctor prescribed?

    Yes, and it happens more quietly than with most medications a doctor hands out. Gabapentin, sold as Neurontin, and its close relative pregabalin, sold as Lyrica, belong to a small family called gabapentinoids, and both can leave you unable to stop without symptoms.

    If you have tried to lower your dose and felt worse, you may already know this. What you may not have been told is that the feeling has a name, that it was predictable, and that it does not mean the original problem is back. How does a medication with a reputation for being harmless do that?

    Dependence forms because the nervous system adapts to whatever it is given.

    Gabapentin binds to part of the calcium channels that nerve cells use to release their signals, and the Neurontin label says plainly that the precise mechanism of its effects is unknown. What clinical experience shows is that a nervous system given a steady daily dose of any calming medication settles into a new normal that assumes the medication will be there.

    One theory is that, when the medication is removed, the adaptation runs in reverse for a while, but the label describes no withdrawal mechanism. In clinical experience it happens at ordinary doses, in people who never took an extra capsule, whatever the label has or has not evaluated.

    Physical dependence is not addiction. Dependence is a medical condition produced by a prescription taken exactly as written, and its treatment is a gradual, planned taper, not a program for a problem you do not have.

    How do you notice gabapentin dependence?

    Patients almost never describe it as dependence. They describe a missed or late dose that brought on anxiety, irritability, a headache, poor sleep, or the pain the medication was started for, within hours rather than days. When the next dose fixes it, most people conclude that they still need the medication.

    A second tell is what happens when a reduction is attempted. Symptoms appear, they look like the original condition, and everyone concludes that it has come back. Pain or anxiety that returns within a day or two of a cut is more often the nervous system objecting than the old illness reappearing on cue.

    The third tell shows up on a dose that has not changed in months: restlessness, poor sleep, a low hum of anxiety, or a fogginess that the next dose only partly relieves. A common pattern is a patient given gabapentin for nerve pain after an operation, kept on it for two years because nobody set a stop date, who meets all three tells in the week a refill runs late.

    What does gabapentin withdrawal feel like?

    It can feel a great deal like benzodiazepine withdrawal. Anxiety, insomnia, sweating, nausea, headache, a racing heart, tremor, and inner restlessness are the usual complaints, and the Neurontin label adds agitation, disorientation, and confusion after sudden stopping, in reports it describes as rare and mostly at higher than recommended doses. The label’s dependence section is thin and admits that dependence has not been evaluated in human studies.

    The label is not thin about one thing. Gabapentin is an antiepileptic medication, and the label warns that these medications should not be stopped abruptly because seizures can increase, directing that any reduction or switch be made gradually over at least a week. Treat that week as a floor, not as a plan for a nervous system that has leaned on the medication for years.

    A few things are never withdrawal until a doctor has said so. A seizure, chest pain, sudden loss of vision or hearing, new or worsening confusion, or thoughts of harming yourself are reasons to get emergency care now, not to wait and see, and if self-harm is in play, call or text 988 first. The label notes that antiepileptic medications can raise the risk of suicidal thoughts, so do not talk yourself out of that call because you assume it is the taper.

    While you are still taking it, the label warns of drowsiness and dizziness, with a caution against driving until you know how it affects you, of serious slowed breathing when it is combined with other sedating medications, benzodiazepines among them, or in people whose breathing is already impaired, and, rarely, of a dangerous drug reaction with rash and fever.

    Why do prescribers overlook it?

    Gabapentin is usually added to a treatment plan rather than planned into it. It arrives to cover nerve pain during another taper, to help with sleep, or after an operation, and no one writes down the day it should end. The first prescription becomes the standing prescription without anyone deciding that it should.

    The second reason is reputation. The Neurontin label states that gabapentin is not a scheduled drug. Some states control it on their own, and pregabalin is federally controlled, but in medicine we have tended to read “not scheduled” as though the nervous system had read the schedule too.

    The third reason is diagnostic. When a reduction brings on anxiety, insomnia, or pain, the simplest explanation on the chart is that the original condition needs continued treatment. Withdrawal is rarely on the list, so the dose goes back up and the question is closed for another year.

    Fortunately, gabapentin can be tapered, and the principles are familiar.

    The Maudsley Deprescribing Guidelines give gabapentinoids their own chapter and apply the same approach they use for benzodiazepines. The taper begins from a stable place, a steady dose on a steady schedule until symptoms have settled, and only then comes the first small cut.

    The cuts then shrink as the dose falls, in what the guidelines call a hyperbolic shape, because the last portion of the dose does a disproportionate share of the work. While a dimmer switch is not a perfect analogy, it holds in one respect: the first part of the turn barely changes the light and the last few degrees change it the most, so a steady hand slows down near the bottom. Cut smaller the lower you go.

    Gabapentin comes in low-strength capsules and, according to the Neurontin label, in a commercial oral solution, so small cuts remain possible at the low end, and where a finer step is needed a compounding pharmacy can prepare a liquid. When symptoms flare after a cut, the dose is held until they settle, and if you take more than one dependence-forming medication, one comes down at a time.

    What if the gabapentin was added during your benzodiazepine taper?

    A prescriber adds it for the sleep, the pain, or the anxiety of a benzodiazepine taper, it helps for a while, and the patient who finishes the benzodiazepine finds a second medication waiting for its own taper. That is how much of the gabapentin dependence Dr. Leeds sees comes to light.

    Dr. Leeds’ rule for anything added during a taper is that its exit plan is written on the day it is started. Anything added without one tends to stay, and the polypharmacy trap is built one helpful addition at a time. If you are offered gabapentin mid-taper, ask then how long it is meant to last and how it will come off.

    If it was added years ago, the answer is not to hurry either medication. Finish the taper you are on, stabilize, and begin the second at the same careful pace, letting your prescriber judge which should come first.

    Is the second taper really starting over?

    No, although it can feel that way. A nervous system that has just finished a benzodiazepine taper is often still sensitized and quick to notice change, so a gabapentin taper taken too fast can hit as hard as the first one did. Some patients barely notice it, others need the same patience they needed the first time, and there is no knowing in advance.

    Yet, you are not starting over. You already know what a window and a wave are, that holding is protection, and that a bad week after a cut is information rather than failure. And, when cuts stop working, the remedy is the one you learned the first time, a longer hold rather than a firmer resolve.

    What should you ask your prescriber?

    Begin with the question nobody asked at the start: what happens if I stop this? Follow it with what the deprescribing plan is, what a slow taper would look like, and whether a liquid form is available for small steps. A prescriber who has thought about gabapentin will have answers, and one who has not will at least have been asked.

    An absent answer is itself useful, because it tells you the plan will have to be made now, with you in the room. The pace belongs to you as much as to the prescriber: if the taper is too fast, the doctor must slow it, and if it is comfortable, the two of you may agree to go a little faster, as tolerated.

    That plan will look much like the one that already worked for you: a stable start, cuts that shrink as the dose falls, and holds when your body asks for them. You already know how to wait through a hard week, and now you know what to ask for.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Kindling and Benzodiazepines: Why Failed Tapers Make the Next One Harder

    Kindling and Benzodiazepines: Why Failed Tapers Make the Next One Harder

    What does kindling mean when people talk about benzodiazepines?

    Kindling is a borrowed word for a nervous system that has become more reactive after repeated abrupt stops. In medicine, we took the term from neurology, where it described a brain that seemed to learn to seize more easily each time it was provoked. In a benzodiazepine patient it describes a second or third withdrawal that arrives sooner, runs hotter, and lasts longer than the first, out of proportion to the dose.

    The word carries its own picture, and it is the one analogy here. Kindling is the small dry wood that catches from a spark, and each time a fire is lit and stamped out, what is left behind catches faster than the fresh wood did. While a brain is not a woodpile, the picture explains why the sensible response is to stop striking sparks.

    So, two questions remain. Is kindling real, and what should it change about the next attempt?

    Why can a second taper feel harder than the first?

    The brain compensates for a benzodiazepine by turning up its own excitability, and when the drug is removed faster than that compensation can unwind, the excess shows itself as withdrawal. Restarting the medication covers it up again, but there is no reason to think it undoes it.

    A too-fast taper is usually not one event but three: a reduction that outran the nervous system, a stretch of severe withdrawal, and a reinstatement. In clinical experience, a nervous system that has lived through a full withdrawal episode tends to react more quickly and more strongly the next time the dose moves.

    When the stops and restarts came from a prescriber rather than from you, the cycle has its own article. This piece is about a nervous system that already carries that history.

    Is kindling proven, and what does the Ashton Manual say?

    Kindling is not proven, and you deserve to hear that plainly. Nobody has settled what changes in the brain after repeated withdrawals, and the evidence for benzodiazepines is thinner than the confidence with which the word gets used. What we have is clinical experience, which varies from one physician to the next.

    Dr. Leeds’ view is that the pattern is recognizable in the people who arrive after two or three failed attempts, and that a history of rapid withdrawals is a reason for more caution, never less. A gentle plan costs little if kindling turns out to be overstated.

    The Ashton Manual does not use the word kindling at all. In fact, Chapter III, in its section on the course of withdrawal, says that eventual success in withdrawal is not affected by previous attempts at withdrawal. Professor C. Heather Ashton wrote that after years of running a withdrawal clinic.

    Both statements can be true, because the manual’s reassurance is about where you end up and kindling is about how hard the next stretch is. The manual itself supplies the reason: Chapter II warns that abrupt or over-rapid withdrawal can produce severe symptoms including convulsions, and Chapter III observes that protracted symptoms are far less common in people who tapered slowly under their own control.

    What harms a nervous system is the abruptness of a stop. So, a previous attempt counts against you only to the degree that it was abrupt, and the next one does not have to be abrupt at all.

    Your symptoms on the last attempt were not in your head.

    People who arrive after repeated failed tapers have often been told that their symptoms were anxiety or a personality trait. Some were told this by the same doctor who set the pace.

    Physical dependence is not addiction. Dependence is the body’s adaptation to a medication taken exactly as prescribed, and withdrawal is what that adaptation looks like when the medication is removed faster than the body can adjust. A taper that did not hold was a pace problem, and pace, unlike a personality trait, can be changed.

    Read as kindling, the same symptoms were the predictable response of a nervous system that had already been provoked once. That argues for a slower plan, and it gives you grounds to expect the plan to work.

    Stabilize before you reduce anything.

    The first move in a taper after failed attempts is to not taper. A nervous system that has just been through withdrawal and reinstatement needs weeks, and sometimes months, at one steady dose before it is ready for a reduction. None of that time is wasted, because nothing is being provoked.

    Stable means predictable, not comfortable. While a rough stretch during a hold can feel like proof that the hold is failing, it is often the nervous system catching up with earlier changes, and the reasons a hold can feel worse have their own article.

    A common pattern: someone came off in ten days at a facility, was restarted within a month, and tried again on a standard outpatient schedule. The second attempt stalled at the second cut, and what worked was three months at a steady dose before anyone touched it.

    Cuts get smaller than last time, and they shrink as the dose falls.

    If the pace that failed last time was the standard pace, the plan this time starts slower than that. The Ashton Manual’s schedules in Chapter II shrink each reduction as the dose comes down, and the Maudsley Deprescribing Guidelines describe reductions in proportion to the current dose. The right size is the one your nervous system tolerates, worked out with your prescriber one cut at a time.

    Precision matters more in a reactive nervous system than in a calm one. Once the dose is below what tablets can be split evenly, a liquid formulation or a compounded preparation keeps each reduction exact, because a dose that varies from day to day is a series of small withdrawals. Unfortunately, precision is often the first thing a rushed plan gives up, and a kindled nervous system does not grade estimates generously.

    A longer-acting benzodiazepine may smooth the ride.

    Short-acting benzodiazepines wear off between doses, and the dip before the next dose is a small withdrawal in its own right. The Ashton Manual, in Chapter II, advises switching to a long-acting benzodiazepine such as diazepam because a short-acting drug cannot give a smooth decline in blood levels.

    That switch is a crossover taper, done in stages over weeks rather than in one swap, and it is not right for everyone. Some people do not tolerate diazepam, so whether to make the change is a decision between you and a prescriber who knows the substitution well.

    Hold through a flare, with a prescriber who will let you.

    Flares happen even in a slow, precise taper. When one arrives, the first move is to stop reducing and stay where you are until the days become predictable again, and the Ashton Manual puts it plainly: if you reach a difficult point, you can stop there for a few weeks if necessary. The Manual adds that you should try to avoid going backwards, while the Maudsley Deprescribing Guidelines allow a return to the last dose at which you were stable, so the two references differ on that point. Whether a particular flare calls for a step back up to the previous dose is a decision for you and your prescriber to make together, case by case, and it is not one to answer alone.

    The most reliable way to kindle a nervous system a third time is a prescriber who hears “I need to slow down” as resistance. So, part of preparing for the next attempt is finding someone who treats your account of the last one as clinical information. A discharge date is an administrative fact, and no nervous system has ever read one.

    The Food and Drug Administration’s 2020 update to the benzodiazepine label warns that abrupt discontinuation or rapid dose reduction can bring on withdrawal reactions, including seizures, that can be life-threatening, and it calls for a gradual taper. Never stop a benzodiazepine suddenly on your own. If you have a seizure, chest pain, or a sudden loss of vision or hearing, or if you are thinking about harming yourself, call 911 or go to the nearest emergency department, and call or text 988 if self-harm is part of it.

    What if you have already been through this two or three times?

    Then you are the person the Ashton Manual’s reassurance was written for. Your previous attempts have not lowered your chances of finishing, and they have told you, at a high price, how fast your nervous system can be asked to move.

    Fortunately, everything that made the earlier attempts fail can be changed on the next one. The pace, the size of each cut, the drug, the willingness to hold, and the person writing the plan are all decisions, and none of them is fixed by what happened before.

    Yet, no physician can honestly give you a timeline, because the manual’s sentence says nothing about how long it takes. What you can hold on to is that the next attempt is made with a partner, at a pace the two of you set together, and that the last failed taper was the last time anyone needs to strike a spark.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Why Do Rapid Benzo Detox Programs Fail?

    Why Do Rapid Benzo Detox Programs Fail?

    What does a rapid benzo detox program actually do?

    A rapid benzodiazepine detox program is a short inpatient stay, usually three to seven days, during which your benzodiazepine is stopped all at once. The symptoms that follow are held down with heavy sedation and a few comfort medications, and some programs add an intravenous infusion of flumazenil, which their marketing calls a “reset” of the brain’s receptors. You go home with a discharge summary that says the job is done.

    If you have taken a benzodiazepine for years, feel worse every month, and have a prescriber who has lost interest, a promise of freedom in a week can look like rescue. These programs fill a real void.

    Yet, the doctors who taper benzodiazepines for a living keep meeting the same patient a few months later, often worse off than before the admission. So, why does a week in a well-staffed unit so often end in months of severe withdrawal?

    Why is “detox” the wrong word for a benzodiazepine?

    Detox is a model built for a drug that leaves the body in days and takes its withdrawal with it. You are watched through the worst of it, and then you go home.

    A benzodiazepine taken for months or years does not behave that way. Chapter I of the Ashton Manual explains that with continued use the brain’s receptors for GABA, or gamma-aminobutyric acid, the nervous system’s main calming signal, become less responsive. That loss of response is what tolerance is, and one theory is that those receptors then need months to regain their old sensitivity.

    Chapter II describes what happens when the drug is removed suddenly: the brain is left in a state of GABA underactivity and the nervous system becomes hyperexcitable, which Chapter III identifies as the source of most withdrawal symptoms. A program that stops the drug on Monday and discharges you on Friday has not shortened that process. It has watched the first few days of it and left.

    A picture may help, though it is not a perfect one.

    Imagine that you have spent a year leaning your full weight against a door that someone else holds shut from the other side. Your legs and back learn to lean, and you stop noticing it. If the person on the other side steps away without warning, you go straight through the doorway and onto the floor.

    If, instead, the door is opened a fraction of an inch each week, your body relearns how to stand, and one day you are standing on your own. While this is not a perfect analogy, the door was never the problem. The lean was, and a lean learned over years takes months to unlearn. A rapid detox opens the door all at once and calls the fall a success.

    Does flumazenil reset anything?

    Flumazenil blocks the benzodiazepine site on the GABA receptor. The U.S. United States Food and Drug Administration (FDA) approved it to reverse benzodiazepine sedation after anesthesia or a procedure and to manage an overdose. Using it to treat dependence is off-label, and its own prescribing information says it is not recommended for benzodiazepine dependence or protracted withdrawal, because that use has not been studied.

    The same prescribing information carries a boxed warning, the strongest warning the FDA places on a drug, and it is about seizures. The label says they are most frequent in people who have been on a benzodiazepine long term, and that the drug can cause convulsions in anyone who is physically dependent on one, which is exactly the person a detox program admits. A seizure is a medical emergency wherever it happens.

    Professor C. Heather Ashton considered flumazenil in Chapter III of the Ashton Manual and concluded that it offered no practical cure for protracted symptoms, because it is very short acting and the relief is only temporary. The evidence for a “reset” is thin, and Dr. Leeds’ view is that flumazenil detox is an off-label procedure with a seizure risk and no substitute for a taper.

    Why does withdrawal go on for months after a week in the hospital?

    Because the sedation ends and the adaptation does not. Comfort medications can hold the acute symptoms down for the length of an admission, and they have little bearing on what your nervous system is doing weeks later. The discharge summary says benzodiazepine free. Your nervous system did not get a copy.

    Patients who have been through one describe a common pattern. A few weeks after discharge they are sleeping two hours a night, cannot tolerate light or sound, and are told by the program that this cannot be withdrawal because the drug is out of their system. Some go on to the long, fluctuating course known as BIND, or benzodiazepine-induced neurological dysfunction.

    Repeated attempts appear to make matters worse. In the experience of doctors who do this work, each cycle of abrupt withdrawal, reinstatement, and another attempt lowers the threshold for severe symptoms the next time, an effect usually called kindling. To be clear, the evidence is thin and the Ashton Manual does not use the word, so what we have is clinical experience, which varies, and no reason to test the question on yourself.

    You are not addicted, so why are you being treated as if you were?

    The program was built for addiction, and it applies that model to everyone who walks through the door. Physical dependence is not addiction. Dependence means that your body has adjusted to a prescribed medication and now needs it to stay stable, and it says nothing about your behavior or your character.

    Dr. Leeds’ position is that a taper timeline set by the length of a program, or by what an insurer will cover, is the wrong starting point. Professor Ashton made a similar point in Chapter II of the Manual: withdrawal centers usually mean a fairly rapid withdrawal, take control away from the patient, and are often followed by setbacks at home.

    Unfortunately, the money runs the other way, and a program paid by the admission has every reason to prefer a seven-day stay to a twelve-month taper. While the people inside these programs are usually trying to help, the model they work in leaves no room for a taper measured in months. This site has more on how detox clinics apply the wrong model to patients who are not addicted.

    What does the slow alternative look like?

    Fortunately, the alternative has been well described for decades. Chapter II of the Ashton Manual says that the rate of withdrawal is an individual matter, that the best judge is usually you, and that whether it takes six, twelve, or eighteen months matters little after years of use. The Maudsley Deprescribing Guidelines add the shape of the curve: reductions that get proportionally smaller as the dose falls.

    In practice that means a gradual reduction over months, with the pace set by how you feel rather than by a calendar, and the freedom to hold steady when symptoms rise. None of it is a schedule to copy from an article, and all of it needs a prescriber who will work within it.

    Is there ever a good reason to be in a hospital during a taper?

    Yes. If you are having thoughts of ending your life, if you are having seizures, if another illness is unstable, or if home is not safe, a hospital can be the right place to be while a taper continues. What matters is what the hospital does with the benzodiazepine once you are there.

    Admitting you so that a slow, monitored reduction can happen safely is good care. Admitting you so that the drug can be stopped in a week is a familiar pattern behind many of the protracted cases that doctors familiar with BIND end up treating. Ask, before you agree to anything, which of the two the program intends.

    Some things are never to be waited out at home, whether or not withdrawal is the cause. A seizure, chest pain, sudden loss of vision or hearing, new weakness on one side of the body, fainting, or a high fever with confusion each needs emergency care, so call 911 or go to the nearest emergency department. If you are thinking about harming yourself, call or text 988, the Suicide & Crisis Lifeline, and tell someone who is with you.

    And, whatever a program has told you, do not stop a benzodiazepine abruptly on your own. If one has already stopped it for you, the way forward is a doctor who will help you, never another fast stop.

    What comes next is slow, and that is the point.

    If you have already been through a rapid detox, none of this is meant to add to the weight of it. The nervous system that was pushed too hard does still heal in most cases, on its own schedule, which no program can shorten.

    The pace of what comes next is a conversation to have with a doctor who is willing to go slowly, to hold when you need to hold, and to decide each step with you. In fact, most people do come off of these medications in the end, and they do it the way the door opens, a little at a time.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.